Eli Lilly & Co. (LLY)
1444.57
+17.29
(+1.21%)
USD |
NYSE |
Nov 13, 16:00
1439.48
-5.09
(-0.35%)
After-Hours: 19:59
Eli Lilly Enterprise Value : 1.388T for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.388T |
| November 11, 2026 | 1.397T |
| November 10, 2026 | 1.393T |
| November 09, 2026 | 1.374T |
| November 06, 2026 | 1.319T |
| November 05, 2026 | 1.329T |
| November 04, 2026 | 1.379T |
| November 03, 2026 | 1.371T |
| November 02, 2026 | 1.373T |
| October 30, 2026 | 1.379T |
| October 29, 2026 | 1.338T |
| October 28, 2026 | 1.257T |
| October 27, 2026 | 1.251T |
| October 26, 2026 | 1.249T |
| October 23, 2026 | 1.243T |
| October 22, 2026 | 1.274T |
| October 21, 2026 | 1.241T |
| October 20, 2026 | 1.253T |
| October 19, 2026 | 1.212T |
| October 16, 2026 | 1.228T |
| October 15, 2026 | 1.223T |
| October 14, 2026 | 1.182T |
| October 13, 2026 | 1.143T |
| October 12, 2026 | 1.158T |
| October 09, 2026 | 1.155T |
| Date | Value |
|---|---|
| October 08, 2026 | 1.145T |
| October 07, 2026 | 1.163T |
| October 06, 2026 | 1.134T |
| October 05, 2026 | 1.121T |
| October 02, 2026 | 1.120T |
| October 01, 2026 | 1.127T |
| September 30, 2026 | 1.134T |
| September 29, 2026 | 1.161T |
| September 28, 2026 | 1.161T |
| September 25, 2026 | 1.160T |
| September 24, 2026 | 1.159T |
| September 23, 2026 | 1.130T |
| September 22, 2026 | 1.148T |
| September 21, 2026 | 1.143T |
| September 18, 2026 | 1.131T |
| September 17, 2026 | 1.131T |
| September 16, 2026 | 1.117T |
| September 15, 2026 | 1.116T |
| September 14, 2026 | 1.118T |
| September 11, 2026 | 1.096T |
| September 10, 2026 | 1.103T |
| September 09, 2026 | 1.104T |
| September 08, 2026 | 1.104T |
| September 04, 2026 | 1.128T |
| September 03, 2026 | 1.138T |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 709.89B |
| Merck & Co., Inc. | 406.57B |
| Pfizer Inc. | 213.03B |
| Bristol Myers Squibb Co. | 159.61B |
| Structure Therapeutics, Inc. | 182.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 6.451B |
| Revenue (Quarterly) | 24.40B |
| Total Expenses (Quarterly) | 17.95B |
| EPS Diluted (Quarterly) | 7.221 |
| Gross Profit Margin (Quarterly) | 83.88% |
| Profit Margin (Quarterly) | 26.44% |
| Earnings Yield | 2.11% |
| Operating Earnings Yield | 3.38% |
| Normalized Earnings Yield | 2.601 |